Cannabis (Ganja) Medical Research - Evidence Supporting Ganja's Value
WEDNESDAY, MARCH 28, 2012 Cannabinoids (Handbook of Experimental Pharmacology). The present book is an outstanding summary of many aspects of cannabinoid research. It provides current knowledge about the pharmacology and therapeutic potential of cannabinoids as well as knowledge about the pharmacology, physiology, and pathology of the endogenous cannabinoid systems. The chapters are written by scientists who have made or are still making major contributions to the field. This book may well help generate novel ideas on how to approach the study of emotions.
Springer: http://www.springer.com/biomed/pharmaceutical+science/book/978-3-540-22565-2
Archive Search: http://archive.org/search.php?query=cannabinoidsPosted by qnbs at 12:02 PM 0 comments Labels: archive, cannabinoids, emotions, endocannabinoid, endogenous, experimental, handbook, internet, knowledge, pathology, pertwee, pharmacology, physiology, pubmed, research, study, therapeutics FRIDAY, DECEMBER 23, 2011. The Medicinal Uses of Cannabis and Cannabinoids.
Cannabis research has moved beyond its use as an illegal recreational drug. Increasingly, focus is on its potential as a therapeutic substance, particularly in serious chronic illnesses such as multiple sclerosis.This new title describes current research findings relating to the medicinal use ofcannabis and cannabinoids. Topics covered include the pharmacology, formulation,safety and efficacy of cannabis as a therapeutic agent; growth and breeding of cannabis as a medicine; cannabis for neuropathic pain treatment and for multiple sclerosis; clinical studies and the development of cannabis-based medicine; and forensic and international control of cannabis. Written by experts in the UK and USA, this is an essential reference for pharmacists ,doctors, pharmacologists and all other healthcare professionals with an interest in cannabis-derived medicines for symptom relief of intractable diseases. Edited by
Amazon: http://www.amazon.com/Medicinal-Uses-Cannabis-Cannabinoids-Geoffrey/dp/0853695172
Google: http://books.google.com/books?id=AznCzOxvrtwC&hl=de&source=gbs_book_other_versions
GW Pharmaceuticals: Research & Development
GW's research explores the potential therapeutic applications of cannabinoids and the endocannabinoid system across a wide range of disease areas. http://www.gwpharm.com/r-and-d.aspx Posted by qnbs at 6:12 PM 1 comments Labels: amazon, cannabinoids, cannabis, google, googlebooks, gw, medicinal, pharmaceutical, pharmaceuticals pharmpress, press, uk, uses TUESDAY, DECEMBER 20, 2011 Journal of Cannabis Therapeutics (2001-2004): http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en
The Journal of Cannabis Therapeutics was published by Haworth Press, Binghamton, New York, and edited by Ethan Russo.
Publication of the Journal of Cannabis Therapeutics ceased in 2004.
The entire contents of the Journal of Cannabis Therapeutics (2001-2004) is now available free online (even to non-members) at the International Association for Cannabinoid Medicines:http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en
2001
Year 2001 - Issue No. 1
Introduction[ Abstract ] [ PDF of the full text ]
Marijuana (Cannabis) as Medicine
Marijuana (Cannabis) as Medicine[ Abstract ] [ PDF of the full text ]
Cancer Chemotherapy
Effects of Smoked Cannabis and Oral delta-9-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy: A Review of State Clinical Trials
[ Abstract ] [ PDF of the full text ]
Endocannabinoid System
The Endocannabinoid System: Can It Contribute to Cannabis Therapeutics?[ Abstract ] [ PDF of the full text ]
History
The Therapeutic Use of Cannabis sativa (L.) in Arabic Medicine[ Abstract ] [ PDF of the full text ]
Eicosanoids
Cannabis and Eicosanoids: A Review of Molecular Pharmacology[ Abstract ] [ PDF of the full text ]
History
Cognoscenti of Cannabis I: Jacques-Joseph Moreau (1804-1884)[ Abstract ] [ PDF of the full text ]
History
Lypemania with Stupor; Tendency to Dementia.-Treatment by the Extract (Resinous Principle) of Cannabis indica.-Cure. Bicètre Hospice[ Abstract ] [ PDF of the full text ]
Politics
Cannabis and the U.S. Controlled Substances Act[ Abstract ] [ PDF of the full text ]
Book Reviews
Book Reviews[ Abstract ] [ PDF of the full text ]
Year 2001 - Issue No. 2
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Cannabis in Azerbaijan
Medicinal Properties of Cannabis According to Medieval Manuscripts of Azerbaijan[ Abstract ] [ PDF of the full text ]
Headache
Hemp for Headache: An In-Depth Historical and Scientific Review of Cannabis in Migraine Treatment
[ Abstract ] [ PDF of the full text ]
Music
Marijuana and Music: A Speculative Exploration[ Abstract ] [ PDF of the full text ]
Year 2001 - Issue No. 3/4
Introduction
Introduction: Cannabis Therapeutics in HIV/AIDS, Plus, a Modest Proposal[ Abstract ] [ PDF of the full text ]
Antiemetic and Appetite Stimulant
Therapeutic Cannabis (Marijuana) as an Antiemetic and Appetite Stimulant in Persons with Acquired Immunodeficiency Syndrome (AIDS)[ Abstract ] [ PDF of the full text ]
History
Medical Marijuana and the AIDS Crisis[ Abstract ] [ PDF of the full text ]
Survey
Marijuana Use in HIV-Positive and AIDS Patients: Results of an Anonymous Mail Survey[ Abstract ] [ PDF of the full text ]
Observational Study
Differential Effects of Medical Marijuana Based on Strain and Route of Administration: A Three-Year Observational Study[ Abstract ] [ PDF of the full text ]
Immune System
Marijuana and Cannabinoids: Effects on Infections, Immunity, and AIDS[ Abstract ] [ PDF of the full text ]
Smoking and the Lung
Effects of Smoked Marijuana on the Lung and Its Immune Defenses: Implications for Medicinal Use in HIV-Infected Patients[ Abstract ] [ PDF of the full text ]
Herbal Synergy
Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?[ Abstract ] [ PDF of the full text ]
Harm Reduction
Harm Reduction Associated with Inhalation and Oral Administration of Cannabis and THC[ Abstract ] [ PDF of the full text ]
Arthritis
Analgesic and Reinforcing Properties of 9-THC-Hemisuccinate in Adjuvant-Arthritic Rats[ Abstract ] [ PDF of the full text ]
Cannabis-Based Medicines
Prospects for New Cannabis-Based Prescription Medicines[ Abstract ] [ PDF of the full text ]
Harm Reduction
Cannabis "Vaporization": A Promising Strategy for Smoke Harm Reduction[ Abstract ] [ PDF of the full text ]
2002
Year 2002 - Issue No. 1
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Chronic Medical Cannabis Use
Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis[ Abstract ] [ PDF of the full text ]
Cystic Fibrosis
Cannabinoids and Cystic Fibrosis: A Novel Approach to Etiology and Therapy[ Abstract ] [ PDF of the full text ]
Origin of Cannabinoid Receptors
Sourcing the Code: Searching for the Evolutionary Origins of Cannabinoid Receptors, Vanilloid Receptors, and Anandamide[ Abstract ] [ PDF of the full text ]
Book Reviews
Book Reviews[ Abstract ] [ PDF of the full text ]
Year 2002 - Issue No. 2
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Music Perception and Hearing
Topographic EEG Changes Accompanying Cannabis-Induced Alteration of Music Perception - Cannabis as a Hearing Aid?[ Abstract ] [ PDF of the full text ]
Interview
An Interview with Willem Scholten and Myra Klee: June 26, 2001[ Abstract ] [ PDF of the full text ]
History
The Medical Use of Cannabis Among the Greeks and Romans[ Abstract ] [ PDF of the full text ]
History
A Homelie Herbe: Medicinal Cannabis in Early England[ Abstract ] [ PDF of the full text ]
Year 2002 - Issue No. 3/4
Introduction
[ Abstract ] [ PDF of the full text ]
Historical Review
Cannabis Treatments in Obstetrics and Gynecology: A Historical Review
[ Abstract ] [ PDF of the full text ]
Endocannabinoids
Endocannabinoid Degradation and Human Fertility
[ Abstract ] [ PDF of the full text ]
Cannabinoids and Feeding
Cannabinoids and Feeding: The Role of the Endogenous Cannabinoid System as a Trigger for Newborn Suckling
[ Abstract ] [ PDF of the full text ]
Hyperemesis Gravidarum
Hyperemesis Gravidarum and Clinical Cannabis: To Eat or Not to Eat?
[ Abstract ] [ PDF of the full text ]
Marijuana Use and Pregnancy
Marijuana Use and Pregnancy
[ Abstract ] [ PDF of the full text ]
Harm Reduction
Cannabis and Harm Reduction: A Nursing Perspective
[ Abstract ] [ PDF of the full text ]
Cannabis in Jamaica
Crack Heads and Roots Daughters: The Therapeutic Use of Cannabis in Jamaica
[ Abstract ] [ PDF of the full text ]
Hashish
One Woman's Work in the Use of Hashish in a Medical Context
[ Abstract ] [ PDF of the full text ]
Tourette Syndrome
Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists
[ Abstract ] [ PDF of the full text ]
Case Report
Personal Account of Medical Use of Cannabis
[ Abstract ] [ PDF of the full text ]
Multiple Sclerosis
Cannabis in Multiple Sclerosis: Women’s Health Concerns
[ Abstract ] [ PDF of the full text ]
2003
Year 2003 - Issue No. 1
Editorial
[ Abstract ] [ PDF of the full text ]
Pharmacokinetics
Clinical pharmacokinetics of cannabinoids
[ Abstract ] [ PDF of the full text ]
Medical Cannabis Use
The acceptance of medicinal marijuana in the U.S.
[ Abstract ] [ PDF of the full text ]
An interview with Markus Storz
[ Abstract ] [ PDF of the full text ]
Year 2003 - Issue No. 2
Editorial
[ Abstract ] [ PDF of the full text ]
Cannabis in HIV/AIDS
Cannabis Use by Persons Living with HIV/AIDS: Patterns and Prevalence of Use
[ Abstract ] [ PDF of the full text ]
Survey
Survey on the Medical Use of Cannabis and THC in Germany
[ Abstract ] [ PDF of the full text ]
Palliative Care
Attitudes and Beliefs about the Use of Cannabis for Symptom Control in a Palliative Population
[ Abstract ] [ PDF of the full text ]
Cultivation of Cannabis
Guidelines for Cultivating Cannabis for Medicinal Purposes [Voorschriften voor de Verbouw van Cannabis voor Medicinale Doeleinden]
[ Abstract ] [ PDF of the full text ]
Meeting report
Cannabinoids and Pain Management Symposium: American Academy of Pain Management 13th Annual Clinical Meeting, 2002, Reno, NV, USA
[ Abstract ] [ PDF of the full text ]
Book Review
Book Review
[ Abstract ] [ PDF of the full text ]
Year 2003 - Issue No. 3/4
Introduction
Cannabis: From Pariah to Prescription[ Abstract ] [ PDF of the full text ]
Abbreviations
GW Pharmaceuticals List of Abbreviations and Definitions of Terms
[ Abstract ] [ PDF of the full text ]
Clinical Study
A Single Centre, Placebo-Controlled, Four Period, Crossover, Tolerability Study Assessing, Pharmacodynamic Effects, Pharmacokinetic Characteristics and Cognitive Profiles of a Single Dose of Three Formulations of Cannabis Based Medicine Extracts (CBMEs) (
[ Abstract ] [ PDF of the full text ]
Clinical Study
A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of
[ Abstract ] [ PDF of the full text ]
Clinical Study
A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215)
[ Abstract ] [ PDF of the full text ]
Clinical Studies
Cannabis and Cannabis Based Medicine Extracts: Additional Results
[ Abstract ] [ PDF of the full text ]
Review and Outlook
Future of Cannabis and Cannabinoids in Therapeutics
[ Abstract ] [ PDF of the full text ]
2004
Year 2004 - Issue No. 1
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Vaporizer
Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds
[ Abstract ] [ PDF of the full text ]
Pharmacodynamics
Clinical Pharmacodynamics of Cannabinoids
[ Abstract ] [ PDF of the full text ]
Alcohol Dependency
Cannabis as a Substitute for Alcohol: A Harm-Reduction Approach
[ Abstract ] [ PDF of the full text ]
International Association for Cannabinoid Medicines (IACM): http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en
Medical Cannabis: http://medicalcannabis.com/Resources/jcant-on-linePosted by qnbs at 7:20 AM 0 commentsLabels: access, cannabinoids, cannabis, endocannabinoid, endocannabinoids, full-text, IACM, journal, medical,medicine, pdf, publication, research, therapeuticsTUESDAY, DECEMBER 13, 2011Cannabis Therapeutics Marijuana Education & Dispensary Safety, ColoradoMarijuana Education and Dispensary Safety (Colorado)
Cannabis Therapeutics: http://cannabistherapeutics.net
Marijuana Education (PDF): http://cannabistherapeutics.net/MarijuanaEducation.pdf
Designed as an in-depth guide to medical marijuana in Colorado, this presentation examines legal, safety, scientific, personal, and societal consequences of the drug’s use as medicine with an intended audience comprised of both the law enforcement and patient communities.The purpose of this booklet is four-fold:
For more information on a particular topic, the following professionals can be contacted at:
Legal Questions:
Attorney Warren Edson, 303-831-8188
Attorney Brian Vicente, 720-890-4247Medical/ Scientific Questions:
Robert Melamede, PHD, 719-262-3135
Matthew Schnur, Researcher, 719-439-0817All questions and inquiries may be sent to:
[email protected]
Cannabis Therapeutics, LLC is the largest medical marijuana resources facility to proudly serve patients of the state of Colorado. Working with local law enforcement, state officials, legal experts, medical physicians, and researchers, Cannabis Therapeutics sets a standard of both safety and consistent quality to its members as well as the community at large. Cannabis Therapeutics: http://cannabistherapeutics.net
Marijuana Education (PDF): http://cannabistherapeutics.net/MarijuanaEducation.pdf
Chemicals in marijuana:
1. Cannabinoids: 78 known as of 2008.
2. Terpenoids: 103 known
3. Fatty Acids: 12 known
4. Non-cannabinoid Phenols: 16 known
5. Flavanoids: 19 known- these are potential antioxidants Many of the cannabinoids and terpenoids found within marijuana work together to create an additive effect called synergy. Synergy refers to an increased effect caused by combining two or more drugs, an effect that could not be caused by either drug alone.Synergy of cannabinoids is supported by the fact that Marinol (synthetic, pure THC), has a higher incidence rate of panic attacks and paranoia than clinical studies utilizing whole marijuana plant.The following list describes comparisons in medical efficacy of marijuana constituents to conventional medications, in addition to illustrating point of potential synergy:
1. CBD, CBG, CBN, β-myrcene (terpenoid), quercitan (flavanoid), and Cannflavin A, are but a few constituents other than THC that exert anti-inflammatory effects.
2. Cannflavin A is 30x more potent than aspirin in reducing inflammation in rheumatoid synovial cells (arthritis model).
3. THC has 20x anti-inflammatory effects of aspirin, twice that of hydrocortisone
4. CBD has anti-inflammatory properties at lower doses than aspirin
5. Quercitan is a powerful antioxidant. Also found to be anticarcinogenic and anti-inflammatory, which may mitigate the potential for marijuana smoking to cause lung cancer.• Source: Chapter 7 of “Medical uses of cannabis and Cannabinoids”, Geoffrey Guy, 2004.
Marijuana is an extremely difficult plant to study for clinical effects due to the variation in the abundant amount of therapeutic chemicals.The scientific method applied to pharmaceuticals does not currently allow forsynergistic therapies, likely because of their variation in outcome between individuals. Ultimately, the true therapeutic potential of marijuana remains untapped until a new scientific method is developed to identify clinical outcomes with varying quantities of multiple chemicals.Devices are now available called vaporizers. Vaporizers do not use fire for the combustion (burning) of marijuana. Instead, they use heat to vaporize the medicinal materials without causing the formation of carcinogens.
Studies have unequivocally confirmed the effectiveness and safety of vaporization.
• Hazekamp, Arno, et al. 2005. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmaceutical Sciences 95: 1308-1317.
The National Institute of Health published research proving that the psychoactive component of marijuana, THC, has a greater antioxidant capacity than both vitamins A and E.
These findings occurred eight years prior to the FDA statement that no valid scientific research supports medical marijuana!
• Hampson, AJ, et al. 1998. Cannabidiol and (-)delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academies of Science 95: 8268-8273.
PDF: http://cannabistherapeutics.net/MarijuanaEducation.pdf Posted by qnbs at 2:34 PM 0 comments Labels: booklet, cannabinoids, cannabis, colorado, contact, dispensary, education, genovations, guide,information, legal, marijuana, pdf, professionals, safety, scientific, state, therapeutics SUNDAY, DECEMBER 4, 2011 Cannabinoid Conference 2011
6th Conference on Cannabinoids in Medicine and 5th European Workshop on Cannabinoid Research, September 8–10, 2011 A joint meeting of the European Workshop on Cannabinoids and the International Association for Cannabinoid Medicines (IACM)
Programs and Abstracts (PDF): http://www.cannabis-med.org/meeting/Bonn2011/abstractbook.pdf
Sponsors:
International Association for Cannabinoid Medicines: http://cannabis-med.org
Internet: http://www.bonn2011.org
ORGANIZING COMMITTEE
Co-Chairs
Franjo Grotenhermen
Andreas Zimmer
Members
Manuel Guzman
Roger Pertwee
Ethan Russo
SCIENTIFIC COMMITTEE
Itai Bab
Javier Fernandez-Ruiz
Franjo Grotenhermen
Manuel Guzman
Roger Pertwee
Ethan Russo
Mark Ware
Andreas Zimmer
CONFERENCE PROGRAM
Opening and Introduction
15:15-16:00 Plenary Lecture I
Daniele Piomelli
The Endocannabinoid System: New tools lead to new insights
Chair: A. Zimmer
16:00-16:30 COFFEE BREAK
16:30-18:15 Session I - Brain functions
Chair: M. Guzman
16:30-17:00 Ken Mackie
Mechanisms of CB1 receptor desensitization
17:00-17:30 Beat Lutz
Cell type-specific functions of the brain's endocannabinoid system
17:30-17:45 Ana Luisa Terzian
The cross-talk between dopamine and cannabinoid in emotions and cognition: the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors
17:45-18:00 Patrik Roser
Auditory mismatch negativity generation in schizophrenia with and without comorbid cannabis use
18:00-18:15 Miriam Schneider
Social rejection in adolescent rats induces persistent alterations in pain perception and CB1 receptor expression - A new animal model with relevance for borderline personality disorder
18:30-21:00 GET-TOGETHER WITH WINE TASTING
Festsaal (see floor plan)
Friday, September 9
09:00-17:00 Registration
09:00-09:45 Plenary Lecture II
George Kunos
The peripheral endocannabinoid/CB1 receptor system as a novel therapeutic target in obesity/metabolic syndrome
Chair: I. Bab
09:45-10:00 COFFEE BREAK
10:00-11:45 Session II - Metabolism and inflammation
Chair: B. Lutz
10:00 - 10:30 Vincenzo Di Marzo
Targeting the peripheral endocannabinoid system with plant cannabinoids and n-3 polyunsaturated fatty acids to Combat abdominal obesity-associated metabolic disorders
10:30-11:00 Sophie Lotersztajn
Cannabinoid receptors in liver pathophysiology: new insights and therapeutic openings
11:00-11:15 Zvi Vogel
Effects of cannabinoids on microglial gene expression and their role in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis
11:15-11:30 Sabine Steffens
Deficiency of fatty acid amide hydrolase is associated with a vulnerable plaque phenotype in atherosclerosis-prone mice
11:30-11:45 Jose Antonio Martinez Orgado
Cannabidiol reduces hypoxic-ischemic brain damage by modulating excitoxicity, oxidative stress and inflammation. Role of CB2 and 5HT1A receptors
11:45-13:00 LUNCH
13:00-15:00 Session III - Neuroinflammation
Chair: S. Maione
13:00-13:30 Javier Fernandez-Ruiz
Anti-inflammatory and neuroprotective potential of Sativex-like medicines in Huntington's disease: from basic research to clinical studies
13:30-14:00 Andreas Zimmer
CB2 receptor signaling in neuroinflammation
14:00-14:30 Andrea Hohmann
Role of endocannabinoid signalling in the control of pain initiation
14:30-14:45 Onintza Sagredo
Potential exidation of 2- AG by COX-2 enhances malonate toxicity in the striatum: Relevance for cannabinoid treatments in Huntington's Disease
14:45-15:00 Judith Alferink
CB2 signaling is required for susceptibility of cerebral malaria
15:00 -17:00 POSTER SESSION I AND COFFEE BREAK
[IACM General Meeting]
17:00-18:30 Session IV - Translational and preclinical studies
Chair: J. Fernandez-Ruiz
17:00-17:30 Manuel Guzman
Therapeutic potential of cannabinoids as anticancer drugs
17:30 - 18:00 Aron Lichtman
Targeting Endocannabinoid Hydrolytic Enzymes to treat Neuropathic and Inflammatory Pain
18:00-18:15 Evelyn Gaffal
CB1 receptor deficiency in epidermal keratinocytes promotes contact allergic inflammation and delays epidermal barrier repair response
18:15-18:30 Ethan Russo
Cannabidiol and TRPV1: Turning down the heat (and pain)
Saturday, September 10
08:30-12:00 Registration
08:45-10:50 Session V- Bone
Chair: I. Bab
08:45-09:15 Itai Bab
Novel Cannabinoid Skeletal Targets
09:15-09.45 Ruth Ross
Cannabinoids and bone biology: latest developments
09:45-10:05 Sabatino Maione
The expression of TRPV1 channel and ofCB1 vs CB2 cannabinoid receptors is modified in osteoclasts from osteoporotic women
10:05-10:20 Thomas Randau
CB2 receptor expression in human spinal mesenchymal stem cells
from patients with osteoporosis
10:20 - 10:35 Jiirg Gertsch
Osteoclastogenesis inhibition by a novel class of biphenyl-type
cannabinoid CB2 receptor inverse agonists
10:35-10:50 COFFEE BREAK
11:05-12:05 Session VI - Herbal cannabis
Chair: W. Notcutt
10:50-11:20 Roger Pertwee
Phytocannabinoid Pharmacology: New Discoveries and Therapeutic Possibilities
11:20-11:35 Jeffrey Hergenrather
Clinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with Crohn's Disease and ulcerative colitis
11:35-11:50 Arno Hazekamp
The medicinal use of cannabis and cannabinoids: an international survey on methods of intake
11:50-12:05 Sarah Martin
Cannabis oils produced by a multiple sclerosis patient reveals the potentials of cannabis when used in its natural form
12:05-13:15 LUNCH
13:15-14:30 POSTER SESSION II
14:30-16:30 Sativex, Nabilone, and Dronabinol
Chair: D. Abrams
14:30-15:00 Philip Robson
Sativex - a clinical overview
15:00-15:30 William Notcutt - Title N.N.
A Retrospective Description of the Use of Nabilone in UK Clinical Practice
15:30-16:00 Tjalling Erkelens
Bedrocan Research and Development - stimulating the development of herbal cannabis based-products
16:00-16:15 Tim Beumer
First in human trial of an oral tablet with A9-THC (Namisol)
16:15-16:30 Franjo Grotenhermen
Practical aspects of a treatment with dronabinol (THC)
16:30-17:00 BUSINESS MEETING
European Workshop on Cannabinoid Research
17:00-18:00 Session VII - Hot topics from the lab and the clinic
Chair: R. Pertwee
17:00-17:15 Stefan Engeli
Circulating endocannabinoids are related to blood pressure in patients with obstructive sleep apnea
17:15-17:30 Attila Olah
Weed against ZIT? Cannabidiol inhibits lipid synthesis of human sebocytes both in vitro and in vivo
17:30-17:45 Linda Klumpers
Demonstrating peripheral restriction ofCB1 antagonist TM 38837 in humans
17:45-18:00 Viktor Rempel
Xanthine derivatives as novel ligands for cannabinoid receptors and the related orphan receptor GPR55
18:00-18:30 Special Presentation
Raphael Mechoulam
Beyond Cannabis and Anandamide
Chair: A. Zimmer
19:30-22:00 CONFERENCE DINNER
POSTER LIST
1 AGE-RELATED CHANGES IN THE ENDOCANNABINOID LEVELS, OXIDATIVE
STRESS AND LYSOSOMAL ACTIVITY IN MICE LACKING CB1 RECEPTOR
A. Piyanova , O. Albayram, K. Michel, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, A. Bilkei- Gorzo
2 ROLE OF CANNABINOID 1 RECEPTORS ON HIPPOCAMPAL GABAERGIC NEURONS IN BRAIN AGING
O. Albayram , J. Alferink, A. Piyanova, K. Monory, B.Lutz, A. Zimmer, A. Bilkei-Gorzo
3 MULTITARGET DRUGS AT CB2 RECEPTOR AND BuChE FOR ALZHEIMER
DISEASE
Gonzalez-Naranjo P. , Perez C, Campillo Nuria E., Giron R., Sanchez E., Martin Ml, Gomez- Canas M., Fernandez-Ruiz J., Romero J., and J.A. Paez
4 THE COMBINATION OF D9-THC AND CANNABIDIOL REDUCES THE COGNITIVE IMPAIRMENT IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE
E. Aso , S. Juves, R. Maldonado, I. Ferrer
5 CANNABINOID RECEPTOR 1 (CB1) KNOCK-OUT AFFECTS BIOCHEMICAL
PROCESSING OF THE AMYLOID PRECURSOR PROTEIN (APP) AND LEADS TO A
DECREASE IN COGNITIVE ABILITIES IN A MOUSE MODEL OF ALZHEIMER'S
DISEASE (AD)
C. Hiebel , C. Stumm, R. Hanstein, H. Nagel, M. Purrio, A. Conrad, B. Lutz, C. Behl and A. B. Clement
6 ANXIOLYTIC-LIKE PROPERTIES OF ST4070, A NOVEL, POTENT AND SELECTIVE REVERSIBLE INHIBITOR OF FAAH
M. Maccarrone, E. M. Marco, C. Rapino, A. Caprioli, F. Borsini, G. Laviola and S. Oddi
7 A STRUCTURE-AFFINITY STUDY ON NEW RESORCINOL "HYBRIDS": ROLE OF
THE AMIDE HEAD ON THE CANNABINOID RECEPTOR INTERACTION
A. Brizzi , M. G. Cascio, F. Aiello, A. Ligresti, V. Brizzi, R. G. Pertwee, F. Corelli and V. Di Marzo
8 EFFECTS OF CANNABIDIOL AND OTHER PHYTOCANNABINOIDS ON
SEROTONIN 5-HT 1A RECEPTORS
M. G. Cascio , D. Bolognini, L. A. Stevenson and R. G. Pertwee
9 TONIC INHIBITORY EFFECT OF ENDOCANNABINOIDS ON HUMAN CONNECTIVE TISSUE- AND MUCOSAL- TYPE MAST CELL FUNCTIONS IN SITU VIA CANNABINOID RECEPTOR 1 (CB1) SIGNALING
K. Sugawara , T. Biro, A. Kromminga, D. Tsuruta, B. I Toth, N. Zakany, T. Hundt, V. Emelianov,
B. F. Gibbs, and R. Paus
10 CANNABINOID RECEPTOR TRAFFICKING IN PERIPHERAL IMMUNE CELLS IS TYROSINE PHOSPHATASE-DEPENDENT
J. Kleyer , S. Nicolussi and J. Gertsch
11 FREQUENCY-DEPENDENT MODULATION OF NORADRENERGIC TRANSMISSION BY CANNABINOIDS IN THE RAT PREFRONTAL CORTEX (PFC)
H. Richter , F. M. Teixeira, S. G. Ferreira, F. Goloncser, A. Kittel, A. Kofalvi, B. Sperlagh
12 INTERACTION OF 2-ARACHIDONOYLGLYCEROL WITH THE GABA A RECEPTOR COMPLEX
C. M. van Rijn and E. Willems-van Bree
13 DEFRAGMENTATION OF THE PERIODS OF IMMOBILITY DURING CHRONIC
ADMINISTRATION OF PHYTOCANNABINOIDS IN RATS
C. M. van Rijn , A. Hafkemeijer, M. LA Jongsma and R. J. Glas
14 PROPOFOL AT THERAPEUTIC DOSE IS NOT A HUMAN FATTY ACID AMIDE
HYDROLASE INHIBITOR
C. Jarzimski, M. Karst, A. A. Zoerner, C. Rakers, M. May, M. Suchy, D. Tsikas, J. K. Krauss, D. Scheinichen, J. Jordan, S. Engeli
15 ANTI-INFLAMMATORY EFFECT OF 5-AMINOSALICYLIC ACID ON THE PPARA SIGNALING SYSTEM IN THE HUMAN ULCERATIVE COLITIS
J. Suarez , Y. S. Romero-Zerbo, L. Marquez, F. J. Bermudez-Silva, M. Iglesias, M. Andreu, F. Rodrfguez de Fonseca
16 LIQUID EXTRACTION OF ENDOCANNABINOIDS WITH TOLUENE REDUCES
MATRIX EFFECTS AND TRANS-ACYLATION OF 2-ARACHIDONOYL GLYCEROL
TO 1-ARACHIDONOYL GLYCEROL
A. A. Zoerner , S. Batkai, S. Engeli, M. T. Suchy, J. Jordan, D. Tsikas
17 SYSTEMATIC CHARACTERIZATION OF ENDOCANNABINOID MICRODIALYSIS
A. A Zoerner , C. Rakers, S. Engeli, S. Batkai, M. May, J. Jordan, D. Tsikas
18 DESIGN AND SYNTHESIS OF NEW QUINOLONE-7-SUBSTITUTED-3-
CARBOXAMIDES AS POTENTIAL CB1 SELECTIVE LIGANDS
M. De Rosa , S. Pasquini, C. Mugnaini, A. Brizzi, F. Corelli, A. Ligresti and V. Di Marzo
19 IMMUNOAFFINITY CHARACTERIZATION OF PEPTIDE ENDOCANNABINOIDS
IDENTIFICATION OF N-TERMINAL EXTENDED PRECURSORS
M. Bauer and J. Gertsch
20a SYNTHESIS OF 1,3,7-TRISUBSTITUTED XANTHINE DERIVATIVES AS LIGANDS
FOR CANNABINOID AND RELATED GPCRS
D. Horn , C. E. Muller
20b XANTHINE DERIVATIVES AS NOVEL LIGANDS FOR CANNABINOID RECEPORS
AND THE RELATED ORPHAN RECEPTOR GPR55
V. Rempel , D. Horn, C. E. Muller
21 DEVELOPMENT OF POTENT ENDOCANNABINOID REUPTAKE INHIBITORS FROM
A PLANT DERIVED A/-ISOBUTYLAMIDE SCAFFOLD
S. Nicolussi, A. Chicca, M. Soeberdt, J. Gertsch
22 THE C385A MISSENSE VARIANT MODULATES ACUTE STRESS RESPONSE IN
HEALTHY HUMANS
A. Dlugos , E. Childs, A. A. Palmer and H. de Wit
23 A MOUSE LINE FOR CELL TYPE-SPECIFIC RESCUE FROM CB1 RECEPTOR
DEFICIENCY
S. Ruhle , G. Marsicano, B. Lutz
24 GENERATION OF CB2 RECEPTOR HUMANIZED MICE
B. Gennequin , D.-M. Otte, X. Miro, M. Karsak, A. M. Zimmer, A. Zimmer
25 GENERATION OF CONDITIONAL KNOCK OUT MICE FOR DIACYLGLYCEROL
LIPASE a AND (3
S. Ternes, D.-M. Otte, A.M. Zimmer, J. Schmidt, C. Hamsch, A. Zimmer
26 EVIDENCE SUPPORTING THE EXISTENCE OF AN ENDOCANNABOID
MEMBRANE TRANSPORTER INVOLVED IN CELLULAR AEA AND 2-AG UPTAKE
A. Chicca , J. Marazzi, S. Nicolussi and J. Gertsch
27 AMINO ACIDS D2.63 AND K373 ARE IMPORTANT FOR MAINTAINING THE CB1R
BINDING POCKET, WHILE RESIDUES K3.28 AND S1.39 ARE INVOLVED IN
SELECTIVE LIGAND RECOGNITION
J. P. Marcu , A. Kapur, M. Trznadel, P. H. Reggio, M. E. Abood
28 DEFINITION OF THE CELLULAR SOURCE OF ELEVATED 2-AG LEVELS IN THE
LIVER AND ANALYSIS OF 2-AG INDUCED CELL DEATH IN HEPATIC STELLATE
CELLS
A. Wojtalla , M. V. Singer, T. Sauerbruch, A. Zimmer, S. V. Siegmund
29 REGULATION OF TYPE 1 CANNABINOID RECEPTORS AND MU OPIOID
RECEPTORS BY MICRORNA AND POSSIBLE CONSEQUENCES ON DRUG
TOLERANCE
C. Borner , J. Kraus, E. Martella, V. Hollt
30 ACUTE AND CHRONIC CANNABINOID TREATMENT DIFFERENTLY AFFECT
ALCOHOL INTAKE IN PUBERTAL AND ADULT RATS
C. M. Friemel , R. Spanagel, M. Schneider
31 INVOLVEMENT OF THE ECB SYSTEM IN HEDONIC REWARD PROCESSING -
MEASURED BY THE PLEASURE ATTENUATED STARTLE PARADIGM
M. Schneider , A. Zimmer, C. Friemel, T. Brand
32 CANNABIDIOL ATTENUATES SOCIAL ISOLATION-INDUCED AGGRESSION IN
MICE
F. V. Gomes , S. F. Lisboa and F. S. Guimaraes
33 DIAGNOSIS OF MAJOR DEPRESSION USING ETHANOLAMINE PHOSPHATE
(EAP): POSSIBLE APPLICATION FOR DEVELOPMENT OF ANTIDEPRESSANT
MANIPULATING THE ENDOCANNABINOID SYSTEM
Y. Ohashi, K. Shinoda, H. Sato, K. Sasaki, H. Yamamoto, T. Ishikawa, N. Kawamura
34 DEMONSTRATING PERIPHERAL RESTRICTION OF NOVEL CANNABINOID CB1
ANTAGONIST TM38837 BY EVALUATING FOR EXPRESSION OF CONDITIONED
FEAR IN MICE
V. Micale , P. K. Norregaard and C. T. Wotjak
35 EFFECTS ON FEAR AND ANXIETY OF AAV VECTOR-MEDIATED
OVEREXPRESSION OF MAGL IN GLUTAMATERGIC NEURONS OF THE
BASOLATERAL AMYGDALA
F. Remmers , S. Guggenhuber, S. Ruehle, B. Lutz
36 AAV-MEDIATED OVEREXPRESSION OF THE CB1 RECEPTOR IN THE MPFC OF
ADULT RATS ALTERS COGNITIVE AND EMOTIONAL BEHAVIOR
A. Goepfrich , M. Klugmann, C. M. Friemel, M. Schneider
37 ACUTE AND CHRONIC EFFECTS OF CANNABINOIDS ON THE BEHAVIOUR OF
ZEBRAFISH EMBRYOS
T. Akhtar , S. Ali, H. Rashidi, F. van der Kooy, R. Verpoorte and M. K. Richardson
38 THE IMPACT OF THE ENDOCANNABINOID SYSTEM ON SOUND LOCALISATION
B. Trattner , S. Berner, B. Grothe and L. Kunz
39 CANNABINOID POTENTIATION OF GLYCINE RECEPTORS CONTRIBUTES TO
CANNABIS-INDUCED ANALGESIA
L. Zhang and W. Xiong
40 THE ROLE OF CB2 RECEPTORS IN MODULATION OF INFLAMMATORY PAIN
I. Racz , A. Markert, J. Gertsch, A. Zimmer
41 TARGETING NEUROPATHIC PAIN THROUGH ENDOCANNABINOID RECEPTOR
SIGNALING
A.-L. Klauke , I. Racz, A. Markert, J. Gertsch, A. Zimmer
42 CB2 RECEPTOR MEDIATES PHAGOCYTOSIS AND SCAR FORMATION AFTER
MYOCARDIAL INFARCTION IN MURINE HEART
G. P. Duerr , T. Heuft, G. Suchan, T. Klaas, A. Welz, A. Zimmer, B. K. Fleischmann, O. Dewald
43 EFFECTS OF HIGH GLUCOSE AND INSULIN ON VASORELAXATION TO
ANANDAMIDE
W.-S. Vanessa Ho
44 THE ENDOCANNABINOID ANANDAMIDE MEDIATES HYPOXIC PULMONARY
VASOCONSTRICTION VIA FATTY ACID AMIDE HYDROLASE (FAAH)
METABOLIZATION PRODUCTS
D. Wenzel , M. Matthey, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, B. K. Fleischmann
45 STRATEGIC LOCALIZATION OF TRPV1 EXPRESSING CELLS IN THE BRAIN
VASCULAR SYSTEM
M. Tauchi and R. Kollmar
46 SINGLE DOSE ADMINISTRATION OF CANNABIDIOL AFTER BRAIN HYPOXIA-
ISCHEMIA AFFORDS LONG-LASTING NEUROPROTECTION IN NEWBORN RATS
Pazos MR, Cinquina V, Gomez A, Layunta R, Mohamed N, Martinez-Orgado J.
47 ENDOCANNABINOID CONTENT IN FETAL BOVINE SERA - UNEXPECTED
EFFECTS ON MONONUCLEAR CELLS AND OSTEOCLASTOGENESIS
J. Marazzi , J. Kleyer, J. M. Viveros Paredes, J. Gertsch
48 OSTEOCLASTOGENESIS INHIBITION BY A NOVEL CLASS OF BIPHENYL-TYPE CANNABINOID CB2 RECEPTOR INVERSE AGONISTS
J. M. Viveros Paredes, W. Schuehly, J. Kleyer, A. Huefner, S. Anavi-Goffer, S. Raduner, K.-H. Altmann and J. Gertsch
49 DO CB1 CANNABINOID RECEPTORS REGULATE INSULIN SIGNALLING IN RAT PRIMARY SKELETAL MUSCLE CELLS?
M. Haddad , K. Tsintzas, S.P.H. Alexander and A.J. Bennett
50 CB1 CANNABINOID RECEPTOR ANTAGONISM INHIBITS BALLOON-INDUCED NEOINTIMA FORMATION IN ATHEROSCLEROTIC MICE
F. Molica , F. Burger, C. M. Matter, A. Thomas, C. Staub, A. Zimmer, B. Cravatt, P. Pacher, S. Steffens
51 THE ENDOCANNABINOID SYSTEM SHOWS DIFFERENT ALTERATIONS IN IN
VITRO AND IN VIVO MODELS OF HUNTINGTON'S DISEASE
M. Maccarrone, M. Bari, N. Battista, M. Valenza, M. Malaponti, G. Catanzaro, C. Di Pancrazio, N. Mastrangelo, D. Centonze, A. Finazzi-Agro, E. Cattaneo and S. Oddi
52 DISEASE-MODIFYING EFFECTS OF WIN55.212-2 IN A MODEL OF MULTIPLE
SCLEROSIS IN MICE: ROLE OF CB1 AND CB2 RECEPTORS
E. de Lago , M. Moreno-Martet, C. Rodrfguez-Cueto, C. Palomo-Garo, C. Garcia, M. Gomez-Ruiz, J. A. Ramos and J. Fernandez-Ruiz
53 EFFECTS OF CANNABIS USE ON SOME IMMUNE PARAMETERS IN PATIENTS
WITH MULTIPLE SCLEROSIS
M. Sexton and N. Stella
54 CANNABIDIOL, NON-PSYCHOACTIVE CANNABINOID, AMELIORATES CLINICAL SYMPTOMS AND DECREASES MICROGLIAL ACTIVATION IN MOG-TREATED MICE
E. Kozela , N. Lev, A. Juknat, M. Pietr, N. Rimmerman, R. Levy, Z. Vogel
55 A NOVEL 3D MODEL OF THE HUMAN CANNABINOID RECEPTOR 2 IN ITS ACTIVE STATE HELPS TO DEVELOP NEW RADIOTRACERS FOR POSITRON EMISSION TOMOGRAPHY (PET)
R. Gunther , W. Deuther-Conrad, S. Fischer, T. Ruhl, J. Steinbach, P. Brust
56 18 FLUORINE-LABELED NITROGEN HETEROCYCLIC DERIVATIVES AS NEW
CANDIDATE FOR CANNABINOID CB2 RECEPTOR PET IMAGING
F. Castelli , G. Saccomanni, S. Bertini, S. Del Carlo, V. Di Marzo, V. Lucchesi, C. Manera, G.
Pascali, P. Salvadori, M. Macchia
57 DEVELOPMENT OF AN ULTRA SENSITIVE LC-MS/MS METHOD FOR THE
SIMULTANEOUS DETERMINATION OF A9-TETRAHYDROCANNABINOL AND ONE OF ITS MAJOR METABOLITES A9-(11-OH) TETRAHYDROCANNABINOL IN HUMAN PLASMA
M. Boterman , T. Beumer, F. Oostebring, A. Meijer and E. Oosting
58 DEVELOPMENT, VALIDATION AND USE OF A LC-MS/MS METHOD TO ASSAY
FAAH ACTIVITY IN BIOLOGICAL SAMPLES
C. Rakers , A. A. Zoerner, S. Batkai, S. Engeli, J. Jordan, D. Tsikas
59 A NEW TLC DENSITOMETRY METHOD IN A KIT-FORMAT FOR COMPLETE
SEPARATION AND VISUALISATION OF ALL CANNABINOIDS IN CANNABIS
SPECIES
R.J. Glas
60 INTESTINAL N-ACYLETHANOLAMINE LEVELS ARE DOWN-REGULATED IN BOTH MICE AND RATS BY SENSING OF DIETARY FAT
T. A. Diep , A. N. Madsen, N. Wellner, B. Hoist and H. S. Hansen
61 CIRCADIAN RHYTHM OF BLOOD ENDOCANNABINOIDS - IS FOOD INTAKE THE KEY TRIGGER?
M. May , S. Batkai, A. A. Zoerner, D. Tsikas, J. Jordan, S. Engeli
62 STUDIES ON THE ANORECTIC EFFECT OF N-ACYLPHOSPHATIDYLETHANO-
LAMINE AND PHOSPHATIDYLETHANOLAMINE IN MICE
N. Wellner , K. Tsuboi, A. N. Madsen, B. Hoist, T. A. Diep, M. Nakao, A. Tokumura, M. P. Burns, D. G. Deutsch, N. Ueda and H. S. Hansen
63 EFFECTS OF CHRONIC ADMINISTRATION OF CANNABINOID RECEPTOR
INVERSE AGONIST (AM 251) ON THE FOOD INTAKE, BODY WEIGHT GAIN AND
OXYGEN CONSUMPTION IN OBESE ZUCKER RATS
I. Merroun , J. M. Porres, G. Urbano, P. Aranda, J. Llopis, M. Errami and M. Lopez-Jurado
64 METABOLIC FINGERPRINTING OF CANNABIS SATIVA L, CANNABINOIDS AND TERPENOIDS FOR CHEMOTAXONOMIC AND DRUG STANDARDIZATION
PURPOSES
J. T. Fischedick , A. Hazekamp, T. Erkelens, Y. H. Choi, R. Verpoorte
65 CANNABINOID RECEPTOR 1 IN HODGKIN LYMPHOMA AND B-CELL NON-HODGKIN LYMPHOMA ENTITIES: EXPRESSION AND FUNCTIONAL RELEVANCE FOR SURVIVAL OF TUMOR CELLS
A. H. Benz , C. Renne, M. Koch, E. Maronde, S. Kallendrusch, B. Rengstl, S. Newrzela, S.
Hartmann, M.-L. Hansmann and F. Dehghani
66 DEVELOPMENT OF CB2 SELECTIVE CANNABINOID RECEPTOR LIGANDS AS
POTENTIAL ANTITUMOR AGENTS
V. Lucchesi , F. Castelli, C. Manera, S. Bertini, S. Del Carlo, A. Ligresti, A. M. Malfitano, G. Saccomanni, V. Di Marzo, M. Bifulco, M. Macchia
67 BASALIOMA TREATMENT WITH INTRATUMORAL INJECTIONS OF A CANNABIS-OIL EXTRACT: A SINGLE-CASE STUDY
J. Pedraza-Valiente
68 IMPROVEMENT OF CLONAL PROPAGATION OF CANNABIS SATIVA L. FOR
PHARMACEUTICAL PRODUCTION
S. Beguerie , S. Casano, G. Grassi
69 CLONING OF PHARMACEUTICAL CANNABIS THROUGH AN AEROPONIC
PROPAGATION SYSTEM
S. Beguerie , S. Casano, G. Grassi
70 ESTIMATION OF USABLE BIOMASS YIELD OF OUTDOOR CULTIVATED CANNABIS SATIVA L. PLANTS
Z. Mehmedic , S. Chandra, H. Lata, I. A. Khan and M. A. ElSohly
71 A QUESTIONNAIRE SURVEY OF PATIENTS PRESCRIBED SATIVEX AS
UNLICENSED MEDICINE
Notcutt, W.
72 GLYCINE RECEPTORS, A NEW TARGET FOR MEDICAL MARIJUANA
L. Zhang and W. Xiong
73 USE OF MEDICINAL CANNABIS IN THE NETHERLANDS
L. Wiinkoop , A. Hazekamp, R. Heerdink
74 MEDICAL CANNABIS USE IN POST-TRAUMATIC STRESS DISORDER: A
NATURALISTIC OBSERVATIONAL STUDY
75 PSYCHOSOCIAL STRESS MODULATES CIRCULATING ANANDAMIDE AND
OTHER N-ACYLETHANOLAMINES IN HEALTHY HUMANS
A. Dluqos , E. Childs, K. Stuhr, C. Hillard, H. de Wit
76 THE EFFECT OF CANNABIS INTOXICATION ON EGO EQUILIBRIUM:
INVESTIGATING THE ACUTE DEVELOPMENTAL IMPACT OF AN ALTERED STATE OF CONSCIOUSNESS
M. Metzqer
77 THE SOCIAL AND BIOETHICAL ASPECTS OF USE OF MEDICINAL CANNABIS IN CROATIA
M. Gold , S. Kantar, K. Svrznjak
78 EVALUATION OF A NEW PLATFORM TO ADMINISTER CANNABINOIDS BY
INHALING: MINIVAP® PORTABLE VAPORIZER
J. Fernandez , A. Hazehamp
79 INTOXICATIONS FOLLOWING RECREATIONAL USE OF HERBAL PRODUCTS
CONTAINING SYNTHETIC CANNABINOIDS
Bela Szabo , Volker Auwarter, Stefan Kneisel and Maren Hermanns-Clausen
Abstract book online:
WEDNESDAY, MARCH 28, 2012 Cannabinoids (Handbook of Experimental Pharmacology). The present book is an outstanding summary of many aspects of cannabinoid research. It provides current knowledge about the pharmacology and therapeutic potential of cannabinoids as well as knowledge about the pharmacology, physiology, and pathology of the endogenous cannabinoid systems. The chapters are written by scientists who have made or are still making major contributions to the field. This book may well help generate novel ideas on how to approach the study of emotions.
Springer: http://www.springer.com/biomed/pharmaceutical+science/book/978-3-540-22565-2
Archive Search: http://archive.org/search.php?query=cannabinoidsPosted by qnbs at 12:02 PM 0 comments Labels: archive, cannabinoids, emotions, endocannabinoid, endogenous, experimental, handbook, internet, knowledge, pathology, pertwee, pharmacology, physiology, pubmed, research, study, therapeutics FRIDAY, DECEMBER 23, 2011. The Medicinal Uses of Cannabis and Cannabinoids.
Cannabis research has moved beyond its use as an illegal recreational drug. Increasingly, focus is on its potential as a therapeutic substance, particularly in serious chronic illnesses such as multiple sclerosis.This new title describes current research findings relating to the medicinal use ofcannabis and cannabinoids. Topics covered include the pharmacology, formulation,safety and efficacy of cannabis as a therapeutic agent; growth and breeding of cannabis as a medicine; cannabis for neuropathic pain treatment and for multiple sclerosis; clinical studies and the development of cannabis-based medicine; and forensic and international control of cannabis. Written by experts in the UK and USA, this is an essential reference for pharmacists ,doctors, pharmacologists and all other healthcare professionals with an interest in cannabis-derived medicines for symptom relief of intractable diseases. Edited by
- Geoffrey W Guy - Executive Chairman, GW Pharmaceuticals, UK
- Brian A Whittle - Scientific Director
- Philip J Robson - Medical Director, GW Pharmaceuticals, UK
Amazon: http://www.amazon.com/Medicinal-Uses-Cannabis-Cannabinoids-Geoffrey/dp/0853695172
Google: http://books.google.com/books?id=AznCzOxvrtwC&hl=de&source=gbs_book_other_versions
GW Pharmaceuticals: Research & Development
GW's research explores the potential therapeutic applications of cannabinoids and the endocannabinoid system across a wide range of disease areas. http://www.gwpharm.com/r-and-d.aspx Posted by qnbs at 6:12 PM 1 comments Labels: amazon, cannabinoids, cannabis, google, googlebooks, gw, medicinal, pharmaceutical, pharmaceuticals pharmpress, press, uk, uses TUESDAY, DECEMBER 20, 2011 Journal of Cannabis Therapeutics (2001-2004): http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en
The Journal of Cannabis Therapeutics was published by Haworth Press, Binghamton, New York, and edited by Ethan Russo.
Publication of the Journal of Cannabis Therapeutics ceased in 2004.
The entire contents of the Journal of Cannabis Therapeutics (2001-2004) is now available free online (even to non-members) at the International Association for Cannabinoid Medicines:http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en
2001
Year 2001 - Issue No. 1
Introduction[ Abstract ] [ PDF of the full text ]
Marijuana (Cannabis) as Medicine
Marijuana (Cannabis) as Medicine[ Abstract ] [ PDF of the full text ]
Cancer Chemotherapy
Effects of Smoked Cannabis and Oral delta-9-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy: A Review of State Clinical Trials
[ Abstract ] [ PDF of the full text ]
Endocannabinoid System
The Endocannabinoid System: Can It Contribute to Cannabis Therapeutics?[ Abstract ] [ PDF of the full text ]
History
The Therapeutic Use of Cannabis sativa (L.) in Arabic Medicine[ Abstract ] [ PDF of the full text ]
Eicosanoids
Cannabis and Eicosanoids: A Review of Molecular Pharmacology[ Abstract ] [ PDF of the full text ]
History
Cognoscenti of Cannabis I: Jacques-Joseph Moreau (1804-1884)[ Abstract ] [ PDF of the full text ]
History
Lypemania with Stupor; Tendency to Dementia.-Treatment by the Extract (Resinous Principle) of Cannabis indica.-Cure. Bicètre Hospice[ Abstract ] [ PDF of the full text ]
Politics
Cannabis and the U.S. Controlled Substances Act[ Abstract ] [ PDF of the full text ]
Book Reviews
Book Reviews[ Abstract ] [ PDF of the full text ]
Year 2001 - Issue No. 2
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Cannabis in Azerbaijan
Medicinal Properties of Cannabis According to Medieval Manuscripts of Azerbaijan[ Abstract ] [ PDF of the full text ]
Headache
Hemp for Headache: An In-Depth Historical and Scientific Review of Cannabis in Migraine Treatment
[ Abstract ] [ PDF of the full text ]
Music
Marijuana and Music: A Speculative Exploration[ Abstract ] [ PDF of the full text ]
Year 2001 - Issue No. 3/4
Introduction
Introduction: Cannabis Therapeutics in HIV/AIDS, Plus, a Modest Proposal[ Abstract ] [ PDF of the full text ]
Antiemetic and Appetite Stimulant
Therapeutic Cannabis (Marijuana) as an Antiemetic and Appetite Stimulant in Persons with Acquired Immunodeficiency Syndrome (AIDS)[ Abstract ] [ PDF of the full text ]
History
Medical Marijuana and the AIDS Crisis[ Abstract ] [ PDF of the full text ]
Survey
Marijuana Use in HIV-Positive and AIDS Patients: Results of an Anonymous Mail Survey[ Abstract ] [ PDF of the full text ]
Observational Study
Differential Effects of Medical Marijuana Based on Strain and Route of Administration: A Three-Year Observational Study[ Abstract ] [ PDF of the full text ]
Immune System
Marijuana and Cannabinoids: Effects on Infections, Immunity, and AIDS[ Abstract ] [ PDF of the full text ]
Smoking and the Lung
Effects of Smoked Marijuana on the Lung and Its Immune Defenses: Implications for Medicinal Use in HIV-Infected Patients[ Abstract ] [ PDF of the full text ]
Herbal Synergy
Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?[ Abstract ] [ PDF of the full text ]
Harm Reduction
Harm Reduction Associated with Inhalation and Oral Administration of Cannabis and THC[ Abstract ] [ PDF of the full text ]
Arthritis
Analgesic and Reinforcing Properties of 9-THC-Hemisuccinate in Adjuvant-Arthritic Rats[ Abstract ] [ PDF of the full text ]
Cannabis-Based Medicines
Prospects for New Cannabis-Based Prescription Medicines[ Abstract ] [ PDF of the full text ]
Harm Reduction
Cannabis "Vaporization": A Promising Strategy for Smoke Harm Reduction[ Abstract ] [ PDF of the full text ]
2002
Year 2002 - Issue No. 1
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Chronic Medical Cannabis Use
Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis[ Abstract ] [ PDF of the full text ]
Cystic Fibrosis
Cannabinoids and Cystic Fibrosis: A Novel Approach to Etiology and Therapy[ Abstract ] [ PDF of the full text ]
Origin of Cannabinoid Receptors
Sourcing the Code: Searching for the Evolutionary Origins of Cannabinoid Receptors, Vanilloid Receptors, and Anandamide[ Abstract ] [ PDF of the full text ]
Book Reviews
Book Reviews[ Abstract ] [ PDF of the full text ]
Year 2002 - Issue No. 2
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Music Perception and Hearing
Topographic EEG Changes Accompanying Cannabis-Induced Alteration of Music Perception - Cannabis as a Hearing Aid?[ Abstract ] [ PDF of the full text ]
Interview
An Interview with Willem Scholten and Myra Klee: June 26, 2001[ Abstract ] [ PDF of the full text ]
History
The Medical Use of Cannabis Among the Greeks and Romans[ Abstract ] [ PDF of the full text ]
History
A Homelie Herbe: Medicinal Cannabis in Early England[ Abstract ] [ PDF of the full text ]
Year 2002 - Issue No. 3/4
Introduction
[ Abstract ] [ PDF of the full text ]
Historical Review
Cannabis Treatments in Obstetrics and Gynecology: A Historical Review
[ Abstract ] [ PDF of the full text ]
Endocannabinoids
Endocannabinoid Degradation and Human Fertility
[ Abstract ] [ PDF of the full text ]
Cannabinoids and Feeding
Cannabinoids and Feeding: The Role of the Endogenous Cannabinoid System as a Trigger for Newborn Suckling
[ Abstract ] [ PDF of the full text ]
Hyperemesis Gravidarum
Hyperemesis Gravidarum and Clinical Cannabis: To Eat or Not to Eat?
[ Abstract ] [ PDF of the full text ]
Marijuana Use and Pregnancy
Marijuana Use and Pregnancy
[ Abstract ] [ PDF of the full text ]
Harm Reduction
Cannabis and Harm Reduction: A Nursing Perspective
[ Abstract ] [ PDF of the full text ]
Cannabis in Jamaica
Crack Heads and Roots Daughters: The Therapeutic Use of Cannabis in Jamaica
[ Abstract ] [ PDF of the full text ]
Hashish
One Woman's Work in the Use of Hashish in a Medical Context
[ Abstract ] [ PDF of the full text ]
Tourette Syndrome
Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists
[ Abstract ] [ PDF of the full text ]
Case Report
Personal Account of Medical Use of Cannabis
[ Abstract ] [ PDF of the full text ]
Multiple Sclerosis
Cannabis in Multiple Sclerosis: Women’s Health Concerns
[ Abstract ] [ PDF of the full text ]
2003
Year 2003 - Issue No. 1
Editorial
[ Abstract ] [ PDF of the full text ]
Pharmacokinetics
Clinical pharmacokinetics of cannabinoids
[ Abstract ] [ PDF of the full text ]
Medical Cannabis Use
The acceptance of medicinal marijuana in the U.S.
[ Abstract ] [ PDF of the full text ]
An interview with Markus Storz
[ Abstract ] [ PDF of the full text ]
Year 2003 - Issue No. 2
Editorial
[ Abstract ] [ PDF of the full text ]
Cannabis in HIV/AIDS
Cannabis Use by Persons Living with HIV/AIDS: Patterns and Prevalence of Use
[ Abstract ] [ PDF of the full text ]
Survey
Survey on the Medical Use of Cannabis and THC in Germany
[ Abstract ] [ PDF of the full text ]
Palliative Care
Attitudes and Beliefs about the Use of Cannabis for Symptom Control in a Palliative Population
[ Abstract ] [ PDF of the full text ]
Cultivation of Cannabis
Guidelines for Cultivating Cannabis for Medicinal Purposes [Voorschriften voor de Verbouw van Cannabis voor Medicinale Doeleinden]
[ Abstract ] [ PDF of the full text ]
Meeting report
Cannabinoids and Pain Management Symposium: American Academy of Pain Management 13th Annual Clinical Meeting, 2002, Reno, NV, USA
[ Abstract ] [ PDF of the full text ]
Book Review
Book Review
[ Abstract ] [ PDF of the full text ]
Year 2003 - Issue No. 3/4
Introduction
Cannabis: From Pariah to Prescription[ Abstract ] [ PDF of the full text ]
Abbreviations
GW Pharmaceuticals List of Abbreviations and Definitions of Terms
[ Abstract ] [ PDF of the full text ]
Clinical Study
A Single Centre, Placebo-Controlled, Four Period, Crossover, Tolerability Study Assessing, Pharmacodynamic Effects, Pharmacokinetic Characteristics and Cognitive Profiles of a Single Dose of Three Formulations of Cannabis Based Medicine Extracts (CBMEs) (
[ Abstract ] [ PDF of the full text ]
Clinical Study
A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of
[ Abstract ] [ PDF of the full text ]
Clinical Study
A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215)
[ Abstract ] [ PDF of the full text ]
Clinical Studies
Cannabis and Cannabis Based Medicine Extracts: Additional Results
[ Abstract ] [ PDF of the full text ]
Review and Outlook
Future of Cannabis and Cannabinoids in Therapeutics
[ Abstract ] [ PDF of the full text ]
2004
Year 2004 - Issue No. 1
Editorial
Editorial[ Abstract ] [ PDF of the full text ]
Vaporizer
Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds
[ Abstract ] [ PDF of the full text ]
Pharmacodynamics
Clinical Pharmacodynamics of Cannabinoids
[ Abstract ] [ PDF of the full text ]
Alcohol Dependency
Cannabis as a Substitute for Alcohol: A Harm-Reduction Approach
[ Abstract ] [ PDF of the full text ]
International Association for Cannabinoid Medicines (IACM): http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en
Medical Cannabis: http://medicalcannabis.com/Resources/jcant-on-linePosted by qnbs at 7:20 AM 0 commentsLabels: access, cannabinoids, cannabis, endocannabinoid, endocannabinoids, full-text, IACM, journal, medical,medicine, pdf, publication, research, therapeuticsTUESDAY, DECEMBER 13, 2011Cannabis Therapeutics Marijuana Education & Dispensary Safety, ColoradoMarijuana Education and Dispensary Safety (Colorado)
Cannabis Therapeutics: http://cannabistherapeutics.net
Marijuana Education (PDF): http://cannabistherapeutics.net/MarijuanaEducation.pdf
Designed as an in-depth guide to medical marijuana in Colorado, this presentation examines legal, safety, scientific, personal, and societal consequences of the drug’s use as medicine with an intended audience comprised of both the law enforcement and patient communities.The purpose of this booklet is four-fold:
- 1. To educate the law enforcement community about the legality of medical marijuana in Colorado.
- 2. To offer proper safety guidelines for the protection of both the patients and the community as dispensaries and cooperatives develop.
- 3. Give a brief background in science, focusing on harmful side effects medical validity, and proper usage guidelines.
- 4. To open a line of friendly communication between representatives of both the medical marijuana and law enforcement communities.
For more information on a particular topic, the following professionals can be contacted at:
Legal Questions:
Attorney Warren Edson, 303-831-8188
Attorney Brian Vicente, 720-890-4247Medical/ Scientific Questions:
Robert Melamede, PHD, 719-262-3135
Matthew Schnur, Researcher, 719-439-0817All questions and inquiries may be sent to:
[email protected]
Cannabis Therapeutics, LLC is the largest medical marijuana resources facility to proudly serve patients of the state of Colorado. Working with local law enforcement, state officials, legal experts, medical physicians, and researchers, Cannabis Therapeutics sets a standard of both safety and consistent quality to its members as well as the community at large. Cannabis Therapeutics: http://cannabistherapeutics.net
Marijuana Education (PDF): http://cannabistherapeutics.net/MarijuanaEducation.pdf
- Issuu: http://issuu.com/qnbs/docs/marijuanaeducation
- Scribd: http://www.scribd.com/doc/75697592
- Internet Archive:http://www.archive.org/details/CannabisTherapeuticsMarijuanaEducation
- The Colorado Medical Marijuana Registry: http://www.cdphe.state.co.us/hs/Medicalmarijuana/index.html
- Legal Documents / Resources: http://www.cdphe.state.co.us/hs/Medicalmarijuana/resources.html
Chemicals in marijuana:
1. Cannabinoids: 78 known as of 2008.
2. Terpenoids: 103 known
3. Fatty Acids: 12 known
4. Non-cannabinoid Phenols: 16 known
5. Flavanoids: 19 known- these are potential antioxidants Many of the cannabinoids and terpenoids found within marijuana work together to create an additive effect called synergy. Synergy refers to an increased effect caused by combining two or more drugs, an effect that could not be caused by either drug alone.Synergy of cannabinoids is supported by the fact that Marinol (synthetic, pure THC), has a higher incidence rate of panic attacks and paranoia than clinical studies utilizing whole marijuana plant.The following list describes comparisons in medical efficacy of marijuana constituents to conventional medications, in addition to illustrating point of potential synergy:
1. CBD, CBG, CBN, β-myrcene (terpenoid), quercitan (flavanoid), and Cannflavin A, are but a few constituents other than THC that exert anti-inflammatory effects.
2. Cannflavin A is 30x more potent than aspirin in reducing inflammation in rheumatoid synovial cells (arthritis model).
3. THC has 20x anti-inflammatory effects of aspirin, twice that of hydrocortisone
4. CBD has anti-inflammatory properties at lower doses than aspirin
5. Quercitan is a powerful antioxidant. Also found to be anticarcinogenic and anti-inflammatory, which may mitigate the potential for marijuana smoking to cause lung cancer.• Source: Chapter 7 of “Medical uses of cannabis and Cannabinoids”, Geoffrey Guy, 2004.
Marijuana is an extremely difficult plant to study for clinical effects due to the variation in the abundant amount of therapeutic chemicals.The scientific method applied to pharmaceuticals does not currently allow forsynergistic therapies, likely because of their variation in outcome between individuals. Ultimately, the true therapeutic potential of marijuana remains untapped until a new scientific method is developed to identify clinical outcomes with varying quantities of multiple chemicals.Devices are now available called vaporizers. Vaporizers do not use fire for the combustion (burning) of marijuana. Instead, they use heat to vaporize the medicinal materials without causing the formation of carcinogens.
Studies have unequivocally confirmed the effectiveness and safety of vaporization.
• Hazekamp, Arno, et al. 2005. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmaceutical Sciences 95: 1308-1317.
The National Institute of Health published research proving that the psychoactive component of marijuana, THC, has a greater antioxidant capacity than both vitamins A and E.
These findings occurred eight years prior to the FDA statement that no valid scientific research supports medical marijuana!
• Hampson, AJ, et al. 1998. Cannabidiol and (-)delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academies of Science 95: 8268-8273.
PDF: http://cannabistherapeutics.net/MarijuanaEducation.pdf Posted by qnbs at 2:34 PM 0 comments Labels: booklet, cannabinoids, cannabis, colorado, contact, dispensary, education, genovations, guide,information, legal, marijuana, pdf, professionals, safety, scientific, state, therapeutics SUNDAY, DECEMBER 4, 2011 Cannabinoid Conference 2011
6th Conference on Cannabinoids in Medicine and 5th European Workshop on Cannabinoid Research, September 8–10, 2011 A joint meeting of the European Workshop on Cannabinoids and the International Association for Cannabinoid Medicines (IACM)
Programs and Abstracts (PDF): http://www.cannabis-med.org/meeting/Bonn2011/abstractbook.pdf
Sponsors:
- Deutsche Forschungsgemeinschaft
- International Society of Neurochemistry
- Bedrocan
- Almirall Hermal
- Bionorica Ethics
- Echo Pharmaceuticals
- THC Pharm
- Meda Pharmaceuticals
International Association for Cannabinoid Medicines: http://cannabis-med.org
Internet: http://www.bonn2011.org
- Issuu: http://issuu.com/qnbs/docs/cannabinoidconferenceabstracts
- Scribd: http://www.scribd.com/doc/75702760
- Internet Archive: http://www.archive.org/details/CannabinoidConference2011
ORGANIZING COMMITTEE
Co-Chairs
Franjo Grotenhermen
Andreas Zimmer
Members
Manuel Guzman
Roger Pertwee
Ethan Russo
SCIENTIFIC COMMITTEE
Itai Bab
Javier Fernandez-Ruiz
Franjo Grotenhermen
Manuel Guzman
Roger Pertwee
Ethan Russo
Mark Ware
Andreas Zimmer
CONFERENCE PROGRAM
Opening and Introduction
15:15-16:00 Plenary Lecture I
Daniele Piomelli
The Endocannabinoid System: New tools lead to new insights
Chair: A. Zimmer
16:00-16:30 COFFEE BREAK
16:30-18:15 Session I - Brain functions
Chair: M. Guzman
16:30-17:00 Ken Mackie
Mechanisms of CB1 receptor desensitization
17:00-17:30 Beat Lutz
Cell type-specific functions of the brain's endocannabinoid system
17:30-17:45 Ana Luisa Terzian
The cross-talk between dopamine and cannabinoid in emotions and cognition: the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors
17:45-18:00 Patrik Roser
Auditory mismatch negativity generation in schizophrenia with and without comorbid cannabis use
18:00-18:15 Miriam Schneider
Social rejection in adolescent rats induces persistent alterations in pain perception and CB1 receptor expression - A new animal model with relevance for borderline personality disorder
18:30-21:00 GET-TOGETHER WITH WINE TASTING
Festsaal (see floor plan)
Friday, September 9
09:00-17:00 Registration
09:00-09:45 Plenary Lecture II
George Kunos
The peripheral endocannabinoid/CB1 receptor system as a novel therapeutic target in obesity/metabolic syndrome
Chair: I. Bab
09:45-10:00 COFFEE BREAK
10:00-11:45 Session II - Metabolism and inflammation
Chair: B. Lutz
10:00 - 10:30 Vincenzo Di Marzo
Targeting the peripheral endocannabinoid system with plant cannabinoids and n-3 polyunsaturated fatty acids to Combat abdominal obesity-associated metabolic disorders
10:30-11:00 Sophie Lotersztajn
Cannabinoid receptors in liver pathophysiology: new insights and therapeutic openings
11:00-11:15 Zvi Vogel
Effects of cannabinoids on microglial gene expression and their role in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis
11:15-11:30 Sabine Steffens
Deficiency of fatty acid amide hydrolase is associated with a vulnerable plaque phenotype in atherosclerosis-prone mice
11:30-11:45 Jose Antonio Martinez Orgado
Cannabidiol reduces hypoxic-ischemic brain damage by modulating excitoxicity, oxidative stress and inflammation. Role of CB2 and 5HT1A receptors
11:45-13:00 LUNCH
13:00-15:00 Session III - Neuroinflammation
Chair: S. Maione
13:00-13:30 Javier Fernandez-Ruiz
Anti-inflammatory and neuroprotective potential of Sativex-like medicines in Huntington's disease: from basic research to clinical studies
13:30-14:00 Andreas Zimmer
CB2 receptor signaling in neuroinflammation
14:00-14:30 Andrea Hohmann
Role of endocannabinoid signalling in the control of pain initiation
14:30-14:45 Onintza Sagredo
Potential exidation of 2- AG by COX-2 enhances malonate toxicity in the striatum: Relevance for cannabinoid treatments in Huntington's Disease
14:45-15:00 Judith Alferink
CB2 signaling is required for susceptibility of cerebral malaria
15:00 -17:00 POSTER SESSION I AND COFFEE BREAK
[IACM General Meeting]
17:00-18:30 Session IV - Translational and preclinical studies
Chair: J. Fernandez-Ruiz
17:00-17:30 Manuel Guzman
Therapeutic potential of cannabinoids as anticancer drugs
17:30 - 18:00 Aron Lichtman
Targeting Endocannabinoid Hydrolytic Enzymes to treat Neuropathic and Inflammatory Pain
18:00-18:15 Evelyn Gaffal
CB1 receptor deficiency in epidermal keratinocytes promotes contact allergic inflammation and delays epidermal barrier repair response
18:15-18:30 Ethan Russo
Cannabidiol and TRPV1: Turning down the heat (and pain)
Saturday, September 10
08:30-12:00 Registration
08:45-10:50 Session V- Bone
Chair: I. Bab
08:45-09:15 Itai Bab
Novel Cannabinoid Skeletal Targets
09:15-09.45 Ruth Ross
Cannabinoids and bone biology: latest developments
09:45-10:05 Sabatino Maione
The expression of TRPV1 channel and ofCB1 vs CB2 cannabinoid receptors is modified in osteoclasts from osteoporotic women
10:05-10:20 Thomas Randau
CB2 receptor expression in human spinal mesenchymal stem cells
from patients with osteoporosis
10:20 - 10:35 Jiirg Gertsch
Osteoclastogenesis inhibition by a novel class of biphenyl-type
cannabinoid CB2 receptor inverse agonists
10:35-10:50 COFFEE BREAK
11:05-12:05 Session VI - Herbal cannabis
Chair: W. Notcutt
10:50-11:20 Roger Pertwee
Phytocannabinoid Pharmacology: New Discoveries and Therapeutic Possibilities
11:20-11:35 Jeffrey Hergenrather
Clinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with Crohn's Disease and ulcerative colitis
11:35-11:50 Arno Hazekamp
The medicinal use of cannabis and cannabinoids: an international survey on methods of intake
11:50-12:05 Sarah Martin
Cannabis oils produced by a multiple sclerosis patient reveals the potentials of cannabis when used in its natural form
12:05-13:15 LUNCH
13:15-14:30 POSTER SESSION II
14:30-16:30 Sativex, Nabilone, and Dronabinol
Chair: D. Abrams
14:30-15:00 Philip Robson
Sativex - a clinical overview
15:00-15:30 William Notcutt - Title N.N.
A Retrospective Description of the Use of Nabilone in UK Clinical Practice
15:30-16:00 Tjalling Erkelens
Bedrocan Research and Development - stimulating the development of herbal cannabis based-products
16:00-16:15 Tim Beumer
First in human trial of an oral tablet with A9-THC (Namisol)
16:15-16:30 Franjo Grotenhermen
Practical aspects of a treatment with dronabinol (THC)
16:30-17:00 BUSINESS MEETING
European Workshop on Cannabinoid Research
17:00-18:00 Session VII - Hot topics from the lab and the clinic
Chair: R. Pertwee
17:00-17:15 Stefan Engeli
Circulating endocannabinoids are related to blood pressure in patients with obstructive sleep apnea
17:15-17:30 Attila Olah
Weed against ZIT? Cannabidiol inhibits lipid synthesis of human sebocytes both in vitro and in vivo
17:30-17:45 Linda Klumpers
Demonstrating peripheral restriction ofCB1 antagonist TM 38837 in humans
17:45-18:00 Viktor Rempel
Xanthine derivatives as novel ligands for cannabinoid receptors and the related orphan receptor GPR55
18:00-18:30 Special Presentation
Raphael Mechoulam
Beyond Cannabis and Anandamide
Chair: A. Zimmer
19:30-22:00 CONFERENCE DINNER
POSTER LIST
1 AGE-RELATED CHANGES IN THE ENDOCANNABINOID LEVELS, OXIDATIVE
STRESS AND LYSOSOMAL ACTIVITY IN MICE LACKING CB1 RECEPTOR
A. Piyanova , O. Albayram, K. Michel, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, A. Bilkei- Gorzo
2 ROLE OF CANNABINOID 1 RECEPTORS ON HIPPOCAMPAL GABAERGIC NEURONS IN BRAIN AGING
O. Albayram , J. Alferink, A. Piyanova, K. Monory, B.Lutz, A. Zimmer, A. Bilkei-Gorzo
3 MULTITARGET DRUGS AT CB2 RECEPTOR AND BuChE FOR ALZHEIMER
DISEASE
Gonzalez-Naranjo P. , Perez C, Campillo Nuria E., Giron R., Sanchez E., Martin Ml, Gomez- Canas M., Fernandez-Ruiz J., Romero J., and J.A. Paez
4 THE COMBINATION OF D9-THC AND CANNABIDIOL REDUCES THE COGNITIVE IMPAIRMENT IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE
E. Aso , S. Juves, R. Maldonado, I. Ferrer
5 CANNABINOID RECEPTOR 1 (CB1) KNOCK-OUT AFFECTS BIOCHEMICAL
PROCESSING OF THE AMYLOID PRECURSOR PROTEIN (APP) AND LEADS TO A
DECREASE IN COGNITIVE ABILITIES IN A MOUSE MODEL OF ALZHEIMER'S
DISEASE (AD)
C. Hiebel , C. Stumm, R. Hanstein, H. Nagel, M. Purrio, A. Conrad, B. Lutz, C. Behl and A. B. Clement
6 ANXIOLYTIC-LIKE PROPERTIES OF ST4070, A NOVEL, POTENT AND SELECTIVE REVERSIBLE INHIBITOR OF FAAH
M. Maccarrone, E. M. Marco, C. Rapino, A. Caprioli, F. Borsini, G. Laviola and S. Oddi
7 A STRUCTURE-AFFINITY STUDY ON NEW RESORCINOL "HYBRIDS": ROLE OF
THE AMIDE HEAD ON THE CANNABINOID RECEPTOR INTERACTION
A. Brizzi , M. G. Cascio, F. Aiello, A. Ligresti, V. Brizzi, R. G. Pertwee, F. Corelli and V. Di Marzo
8 EFFECTS OF CANNABIDIOL AND OTHER PHYTOCANNABINOIDS ON
SEROTONIN 5-HT 1A RECEPTORS
M. G. Cascio , D. Bolognini, L. A. Stevenson and R. G. Pertwee
9 TONIC INHIBITORY EFFECT OF ENDOCANNABINOIDS ON HUMAN CONNECTIVE TISSUE- AND MUCOSAL- TYPE MAST CELL FUNCTIONS IN SITU VIA CANNABINOID RECEPTOR 1 (CB1) SIGNALING
K. Sugawara , T. Biro, A. Kromminga, D. Tsuruta, B. I Toth, N. Zakany, T. Hundt, V. Emelianov,
B. F. Gibbs, and R. Paus
10 CANNABINOID RECEPTOR TRAFFICKING IN PERIPHERAL IMMUNE CELLS IS TYROSINE PHOSPHATASE-DEPENDENT
J. Kleyer , S. Nicolussi and J. Gertsch
11 FREQUENCY-DEPENDENT MODULATION OF NORADRENERGIC TRANSMISSION BY CANNABINOIDS IN THE RAT PREFRONTAL CORTEX (PFC)
H. Richter , F. M. Teixeira, S. G. Ferreira, F. Goloncser, A. Kittel, A. Kofalvi, B. Sperlagh
12 INTERACTION OF 2-ARACHIDONOYLGLYCEROL WITH THE GABA A RECEPTOR COMPLEX
C. M. van Rijn and E. Willems-van Bree
13 DEFRAGMENTATION OF THE PERIODS OF IMMOBILITY DURING CHRONIC
ADMINISTRATION OF PHYTOCANNABINOIDS IN RATS
C. M. van Rijn , A. Hafkemeijer, M. LA Jongsma and R. J. Glas
14 PROPOFOL AT THERAPEUTIC DOSE IS NOT A HUMAN FATTY ACID AMIDE
HYDROLASE INHIBITOR
C. Jarzimski, M. Karst, A. A. Zoerner, C. Rakers, M. May, M. Suchy, D. Tsikas, J. K. Krauss, D. Scheinichen, J. Jordan, S. Engeli
15 ANTI-INFLAMMATORY EFFECT OF 5-AMINOSALICYLIC ACID ON THE PPARA SIGNALING SYSTEM IN THE HUMAN ULCERATIVE COLITIS
J. Suarez , Y. S. Romero-Zerbo, L. Marquez, F. J. Bermudez-Silva, M. Iglesias, M. Andreu, F. Rodrfguez de Fonseca
16 LIQUID EXTRACTION OF ENDOCANNABINOIDS WITH TOLUENE REDUCES
MATRIX EFFECTS AND TRANS-ACYLATION OF 2-ARACHIDONOYL GLYCEROL
TO 1-ARACHIDONOYL GLYCEROL
A. A. Zoerner , S. Batkai, S. Engeli, M. T. Suchy, J. Jordan, D. Tsikas
17 SYSTEMATIC CHARACTERIZATION OF ENDOCANNABINOID MICRODIALYSIS
A. A Zoerner , C. Rakers, S. Engeli, S. Batkai, M. May, J. Jordan, D. Tsikas
18 DESIGN AND SYNTHESIS OF NEW QUINOLONE-7-SUBSTITUTED-3-
CARBOXAMIDES AS POTENTIAL CB1 SELECTIVE LIGANDS
M. De Rosa , S. Pasquini, C. Mugnaini, A. Brizzi, F. Corelli, A. Ligresti and V. Di Marzo
19 IMMUNOAFFINITY CHARACTERIZATION OF PEPTIDE ENDOCANNABINOIDS
IDENTIFICATION OF N-TERMINAL EXTENDED PRECURSORS
M. Bauer and J. Gertsch
20a SYNTHESIS OF 1,3,7-TRISUBSTITUTED XANTHINE DERIVATIVES AS LIGANDS
FOR CANNABINOID AND RELATED GPCRS
D. Horn , C. E. Muller
20b XANTHINE DERIVATIVES AS NOVEL LIGANDS FOR CANNABINOID RECEPORS
AND THE RELATED ORPHAN RECEPTOR GPR55
V. Rempel , D. Horn, C. E. Muller
21 DEVELOPMENT OF POTENT ENDOCANNABINOID REUPTAKE INHIBITORS FROM
A PLANT DERIVED A/-ISOBUTYLAMIDE SCAFFOLD
S. Nicolussi, A. Chicca, M. Soeberdt, J. Gertsch
22 THE C385A MISSENSE VARIANT MODULATES ACUTE STRESS RESPONSE IN
HEALTHY HUMANS
A. Dlugos , E. Childs, A. A. Palmer and H. de Wit
23 A MOUSE LINE FOR CELL TYPE-SPECIFIC RESCUE FROM CB1 RECEPTOR
DEFICIENCY
S. Ruhle , G. Marsicano, B. Lutz
24 GENERATION OF CB2 RECEPTOR HUMANIZED MICE
B. Gennequin , D.-M. Otte, X. Miro, M. Karsak, A. M. Zimmer, A. Zimmer
25 GENERATION OF CONDITIONAL KNOCK OUT MICE FOR DIACYLGLYCEROL
LIPASE a AND (3
S. Ternes, D.-M. Otte, A.M. Zimmer, J. Schmidt, C. Hamsch, A. Zimmer
26 EVIDENCE SUPPORTING THE EXISTENCE OF AN ENDOCANNABOID
MEMBRANE TRANSPORTER INVOLVED IN CELLULAR AEA AND 2-AG UPTAKE
A. Chicca , J. Marazzi, S. Nicolussi and J. Gertsch
27 AMINO ACIDS D2.63 AND K373 ARE IMPORTANT FOR MAINTAINING THE CB1R
BINDING POCKET, WHILE RESIDUES K3.28 AND S1.39 ARE INVOLVED IN
SELECTIVE LIGAND RECOGNITION
J. P. Marcu , A. Kapur, M. Trznadel, P. H. Reggio, M. E. Abood
28 DEFINITION OF THE CELLULAR SOURCE OF ELEVATED 2-AG LEVELS IN THE
LIVER AND ANALYSIS OF 2-AG INDUCED CELL DEATH IN HEPATIC STELLATE
CELLS
A. Wojtalla , M. V. Singer, T. Sauerbruch, A. Zimmer, S. V. Siegmund
29 REGULATION OF TYPE 1 CANNABINOID RECEPTORS AND MU OPIOID
RECEPTORS BY MICRORNA AND POSSIBLE CONSEQUENCES ON DRUG
TOLERANCE
C. Borner , J. Kraus, E. Martella, V. Hollt
30 ACUTE AND CHRONIC CANNABINOID TREATMENT DIFFERENTLY AFFECT
ALCOHOL INTAKE IN PUBERTAL AND ADULT RATS
C. M. Friemel , R. Spanagel, M. Schneider
31 INVOLVEMENT OF THE ECB SYSTEM IN HEDONIC REWARD PROCESSING -
MEASURED BY THE PLEASURE ATTENUATED STARTLE PARADIGM
M. Schneider , A. Zimmer, C. Friemel, T. Brand
32 CANNABIDIOL ATTENUATES SOCIAL ISOLATION-INDUCED AGGRESSION IN
MICE
F. V. Gomes , S. F. Lisboa and F. S. Guimaraes
33 DIAGNOSIS OF MAJOR DEPRESSION USING ETHANOLAMINE PHOSPHATE
(EAP): POSSIBLE APPLICATION FOR DEVELOPMENT OF ANTIDEPRESSANT
MANIPULATING THE ENDOCANNABINOID SYSTEM
Y. Ohashi, K. Shinoda, H. Sato, K. Sasaki, H. Yamamoto, T. Ishikawa, N. Kawamura
34 DEMONSTRATING PERIPHERAL RESTRICTION OF NOVEL CANNABINOID CB1
ANTAGONIST TM38837 BY EVALUATING FOR EXPRESSION OF CONDITIONED
FEAR IN MICE
V. Micale , P. K. Norregaard and C. T. Wotjak
35 EFFECTS ON FEAR AND ANXIETY OF AAV VECTOR-MEDIATED
OVEREXPRESSION OF MAGL IN GLUTAMATERGIC NEURONS OF THE
BASOLATERAL AMYGDALA
F. Remmers , S. Guggenhuber, S. Ruehle, B. Lutz
36 AAV-MEDIATED OVEREXPRESSION OF THE CB1 RECEPTOR IN THE MPFC OF
ADULT RATS ALTERS COGNITIVE AND EMOTIONAL BEHAVIOR
A. Goepfrich , M. Klugmann, C. M. Friemel, M. Schneider
37 ACUTE AND CHRONIC EFFECTS OF CANNABINOIDS ON THE BEHAVIOUR OF
ZEBRAFISH EMBRYOS
T. Akhtar , S. Ali, H. Rashidi, F. van der Kooy, R. Verpoorte and M. K. Richardson
38 THE IMPACT OF THE ENDOCANNABINOID SYSTEM ON SOUND LOCALISATION
B. Trattner , S. Berner, B. Grothe and L. Kunz
39 CANNABINOID POTENTIATION OF GLYCINE RECEPTORS CONTRIBUTES TO
CANNABIS-INDUCED ANALGESIA
L. Zhang and W. Xiong
40 THE ROLE OF CB2 RECEPTORS IN MODULATION OF INFLAMMATORY PAIN
I. Racz , A. Markert, J. Gertsch, A. Zimmer
41 TARGETING NEUROPATHIC PAIN THROUGH ENDOCANNABINOID RECEPTOR
SIGNALING
A.-L. Klauke , I. Racz, A. Markert, J. Gertsch, A. Zimmer
42 CB2 RECEPTOR MEDIATES PHAGOCYTOSIS AND SCAR FORMATION AFTER
MYOCARDIAL INFARCTION IN MURINE HEART
G. P. Duerr , T. Heuft, G. Suchan, T. Klaas, A. Welz, A. Zimmer, B. K. Fleischmann, O. Dewald
43 EFFECTS OF HIGH GLUCOSE AND INSULIN ON VASORELAXATION TO
ANANDAMIDE
W.-S. Vanessa Ho
44 THE ENDOCANNABINOID ANANDAMIDE MEDIATES HYPOXIC PULMONARY
VASOCONSTRICTION VIA FATTY ACID AMIDE HYDROLASE (FAAH)
METABOLIZATION PRODUCTS
D. Wenzel , M. Matthey, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, B. K. Fleischmann
45 STRATEGIC LOCALIZATION OF TRPV1 EXPRESSING CELLS IN THE BRAIN
VASCULAR SYSTEM
M. Tauchi and R. Kollmar
46 SINGLE DOSE ADMINISTRATION OF CANNABIDIOL AFTER BRAIN HYPOXIA-
ISCHEMIA AFFORDS LONG-LASTING NEUROPROTECTION IN NEWBORN RATS
Pazos MR, Cinquina V, Gomez A, Layunta R, Mohamed N, Martinez-Orgado J.
47 ENDOCANNABINOID CONTENT IN FETAL BOVINE SERA - UNEXPECTED
EFFECTS ON MONONUCLEAR CELLS AND OSTEOCLASTOGENESIS
J. Marazzi , J. Kleyer, J. M. Viveros Paredes, J. Gertsch
48 OSTEOCLASTOGENESIS INHIBITION BY A NOVEL CLASS OF BIPHENYL-TYPE CANNABINOID CB2 RECEPTOR INVERSE AGONISTS
J. M. Viveros Paredes, W. Schuehly, J. Kleyer, A. Huefner, S. Anavi-Goffer, S. Raduner, K.-H. Altmann and J. Gertsch
49 DO CB1 CANNABINOID RECEPTORS REGULATE INSULIN SIGNALLING IN RAT PRIMARY SKELETAL MUSCLE CELLS?
M. Haddad , K. Tsintzas, S.P.H. Alexander and A.J. Bennett
50 CB1 CANNABINOID RECEPTOR ANTAGONISM INHIBITS BALLOON-INDUCED NEOINTIMA FORMATION IN ATHEROSCLEROTIC MICE
F. Molica , F. Burger, C. M. Matter, A. Thomas, C. Staub, A. Zimmer, B. Cravatt, P. Pacher, S. Steffens
51 THE ENDOCANNABINOID SYSTEM SHOWS DIFFERENT ALTERATIONS IN IN
VITRO AND IN VIVO MODELS OF HUNTINGTON'S DISEASE
M. Maccarrone, M. Bari, N. Battista, M. Valenza, M. Malaponti, G. Catanzaro, C. Di Pancrazio, N. Mastrangelo, D. Centonze, A. Finazzi-Agro, E. Cattaneo and S. Oddi
52 DISEASE-MODIFYING EFFECTS OF WIN55.212-2 IN A MODEL OF MULTIPLE
SCLEROSIS IN MICE: ROLE OF CB1 AND CB2 RECEPTORS
E. de Lago , M. Moreno-Martet, C. Rodrfguez-Cueto, C. Palomo-Garo, C. Garcia, M. Gomez-Ruiz, J. A. Ramos and J. Fernandez-Ruiz
53 EFFECTS OF CANNABIS USE ON SOME IMMUNE PARAMETERS IN PATIENTS
WITH MULTIPLE SCLEROSIS
M. Sexton and N. Stella
54 CANNABIDIOL, NON-PSYCHOACTIVE CANNABINOID, AMELIORATES CLINICAL SYMPTOMS AND DECREASES MICROGLIAL ACTIVATION IN MOG-TREATED MICE
E. Kozela , N. Lev, A. Juknat, M. Pietr, N. Rimmerman, R. Levy, Z. Vogel
55 A NOVEL 3D MODEL OF THE HUMAN CANNABINOID RECEPTOR 2 IN ITS ACTIVE STATE HELPS TO DEVELOP NEW RADIOTRACERS FOR POSITRON EMISSION TOMOGRAPHY (PET)
R. Gunther , W. Deuther-Conrad, S. Fischer, T. Ruhl, J. Steinbach, P. Brust
56 18 FLUORINE-LABELED NITROGEN HETEROCYCLIC DERIVATIVES AS NEW
CANDIDATE FOR CANNABINOID CB2 RECEPTOR PET IMAGING
F. Castelli , G. Saccomanni, S. Bertini, S. Del Carlo, V. Di Marzo, V. Lucchesi, C. Manera, G.
Pascali, P. Salvadori, M. Macchia
57 DEVELOPMENT OF AN ULTRA SENSITIVE LC-MS/MS METHOD FOR THE
SIMULTANEOUS DETERMINATION OF A9-TETRAHYDROCANNABINOL AND ONE OF ITS MAJOR METABOLITES A9-(11-OH) TETRAHYDROCANNABINOL IN HUMAN PLASMA
M. Boterman , T. Beumer, F. Oostebring, A. Meijer and E. Oosting
58 DEVELOPMENT, VALIDATION AND USE OF A LC-MS/MS METHOD TO ASSAY
FAAH ACTIVITY IN BIOLOGICAL SAMPLES
C. Rakers , A. A. Zoerner, S. Batkai, S. Engeli, J. Jordan, D. Tsikas
59 A NEW TLC DENSITOMETRY METHOD IN A KIT-FORMAT FOR COMPLETE
SEPARATION AND VISUALISATION OF ALL CANNABINOIDS IN CANNABIS
SPECIES
R.J. Glas
60 INTESTINAL N-ACYLETHANOLAMINE LEVELS ARE DOWN-REGULATED IN BOTH MICE AND RATS BY SENSING OF DIETARY FAT
T. A. Diep , A. N. Madsen, N. Wellner, B. Hoist and H. S. Hansen
61 CIRCADIAN RHYTHM OF BLOOD ENDOCANNABINOIDS - IS FOOD INTAKE THE KEY TRIGGER?
M. May , S. Batkai, A. A. Zoerner, D. Tsikas, J. Jordan, S. Engeli
62 STUDIES ON THE ANORECTIC EFFECT OF N-ACYLPHOSPHATIDYLETHANO-
LAMINE AND PHOSPHATIDYLETHANOLAMINE IN MICE
N. Wellner , K. Tsuboi, A. N. Madsen, B. Hoist, T. A. Diep, M. Nakao, A. Tokumura, M. P. Burns, D. G. Deutsch, N. Ueda and H. S. Hansen
63 EFFECTS OF CHRONIC ADMINISTRATION OF CANNABINOID RECEPTOR
INVERSE AGONIST (AM 251) ON THE FOOD INTAKE, BODY WEIGHT GAIN AND
OXYGEN CONSUMPTION IN OBESE ZUCKER RATS
I. Merroun , J. M. Porres, G. Urbano, P. Aranda, J. Llopis, M. Errami and M. Lopez-Jurado
64 METABOLIC FINGERPRINTING OF CANNABIS SATIVA L, CANNABINOIDS AND TERPENOIDS FOR CHEMOTAXONOMIC AND DRUG STANDARDIZATION
PURPOSES
J. T. Fischedick , A. Hazekamp, T. Erkelens, Y. H. Choi, R. Verpoorte
65 CANNABINOID RECEPTOR 1 IN HODGKIN LYMPHOMA AND B-CELL NON-HODGKIN LYMPHOMA ENTITIES: EXPRESSION AND FUNCTIONAL RELEVANCE FOR SURVIVAL OF TUMOR CELLS
A. H. Benz , C. Renne, M. Koch, E. Maronde, S. Kallendrusch, B. Rengstl, S. Newrzela, S.
Hartmann, M.-L. Hansmann and F. Dehghani
66 DEVELOPMENT OF CB2 SELECTIVE CANNABINOID RECEPTOR LIGANDS AS
POTENTIAL ANTITUMOR AGENTS
V. Lucchesi , F. Castelli, C. Manera, S. Bertini, S. Del Carlo, A. Ligresti, A. M. Malfitano, G. Saccomanni, V. Di Marzo, M. Bifulco, M. Macchia
67 BASALIOMA TREATMENT WITH INTRATUMORAL INJECTIONS OF A CANNABIS-OIL EXTRACT: A SINGLE-CASE STUDY
J. Pedraza-Valiente
68 IMPROVEMENT OF CLONAL PROPAGATION OF CANNABIS SATIVA L. FOR
PHARMACEUTICAL PRODUCTION
S. Beguerie , S. Casano, G. Grassi
69 CLONING OF PHARMACEUTICAL CANNABIS THROUGH AN AEROPONIC
PROPAGATION SYSTEM
S. Beguerie , S. Casano, G. Grassi
70 ESTIMATION OF USABLE BIOMASS YIELD OF OUTDOOR CULTIVATED CANNABIS SATIVA L. PLANTS
Z. Mehmedic , S. Chandra, H. Lata, I. A. Khan and M. A. ElSohly
71 A QUESTIONNAIRE SURVEY OF PATIENTS PRESCRIBED SATIVEX AS
UNLICENSED MEDICINE
Notcutt, W.
72 GLYCINE RECEPTORS, A NEW TARGET FOR MEDICAL MARIJUANA
L. Zhang and W. Xiong
73 USE OF MEDICINAL CANNABIS IN THE NETHERLANDS
L. Wiinkoop , A. Hazekamp, R. Heerdink
74 MEDICAL CANNABIS USE IN POST-TRAUMATIC STRESS DISORDER: A
NATURALISTIC OBSERVATIONAL STUDY
75 PSYCHOSOCIAL STRESS MODULATES CIRCULATING ANANDAMIDE AND
OTHER N-ACYLETHANOLAMINES IN HEALTHY HUMANS
A. Dluqos , E. Childs, K. Stuhr, C. Hillard, H. de Wit
76 THE EFFECT OF CANNABIS INTOXICATION ON EGO EQUILIBRIUM:
INVESTIGATING THE ACUTE DEVELOPMENTAL IMPACT OF AN ALTERED STATE OF CONSCIOUSNESS
M. Metzqer
77 THE SOCIAL AND BIOETHICAL ASPECTS OF USE OF MEDICINAL CANNABIS IN CROATIA
M. Gold , S. Kantar, K. Svrznjak
78 EVALUATION OF A NEW PLATFORM TO ADMINISTER CANNABINOIDS BY
INHALING: MINIVAP® PORTABLE VAPORIZER
J. Fernandez , A. Hazehamp
79 INTOXICATIONS FOLLOWING RECREATIONAL USE OF HERBAL PRODUCTS
CONTAINING SYNTHETIC CANNABINOIDS
Bela Szabo , Volker Auwarter, Stefan Kneisel and Maren Hermanns-Clausen
Abstract book online:
- Issuu: http://issuu.com/qnbs/docs/cannabinoidconferenceabstracts
- Scribd: http://www.scribd.com/doc/75702760
- Internet Archive: http://www.archive.org/details/CannabinoidConference2011